Avid Bioservices Inc (CDMO)

[biopharm]

I agree the elephant in the room

Some things take time, and time is all I had ....it has always been about the IP assets

Once more info goes public ...many more IIS will conclude it was by NO ACCIDENT that John Springs Stafford showed up

It was by NO ACCIDENT that Ampersand Capital plays such a role to have their crew forming multiple CDMOs and PS Targeting based insights into Biomarkers ...

Look at all the CDMOs etc ...some are born fresh with nothing

...yet, Ampersand just had to have those 15% royalties based upon IP assets manufacturing etc etc

The business plan of Avid CDMO Avid Bioservices includes FDA approvals based upon IP assets / Biomarkers / surrogate endpoints ...etc etc

I doubt JP Morgan will be blinded ... or they are even more concerned about their other PS Targeting investments

Since Big Pharma missed the boat on the Targeting of flipped PS ...that has that "immune effector function" and NIH / FBI missed the boat on IP sabotage re: cancer cures...(FBI may have more news soon though proving they didn't miss the boat...just too many Merckly boats roaming about..)

It is 100% possible that many IIS have missed the boat on the true value of the IP assets once held by Peregrine Pharmaceuticals and now part of the business model of Avid Bioservices CDMO

Interesting, I remember "immune effector function " somewhere along the way...that just may reward every CDMO investors in ways rarely seen

...
The program managers were looking for exciting new scientific results, Lauer says. But they also found troubling discrepancies between the affiliations and funding that a grantee had reported to NIH and what they wrote in their papers.

“It’s fascinating,” Lauer says. The reporting discrepancy “had been going on for a number of years, apparently, but it took a long time before we noticed it. That’s when we decided there was something going on.”

Initial resistance
NIH’s first step was to notify all grantee institutions that it was launching an investigation. That August 2018 letter, from NIH Director Francis Collins, was followed by inquiries from Lauer about specific researchers.

Many universities pushed back, he says, telling him the agency’s suspicions were misplaced. “What we heard was that there’s nothing going on,” Lauer says. A typical response from a senior university official went like this, according to Lauer: “The faculty member says he’s never been to China, he doesn’t receive any support from the government, and he has no affiliation with any Chinese university. They told us we’re just blowing smoke.”

But Lauer says most university officials changed their tune after NIH showed them evidence that included grant numbers from foreign funders and employment contracts with foreign institutions. “So then what happens is that the university digs a bit deeper and finds that, yes, there is a lot going on,” he says.
...
...